101 rejections at the USPTO plummeted in computational biology in 2023! We analyzed office actions since 2008 related to bioinformatics/computer [1] technologies. 3 Interesting Takeaways re: Patent Eligibility [2] (See Graph): After 2014 (Alice S. Ct. decision), percent of 101 rejections increased substantially in these computer-related art units. From ~10-40% in 2013 to 70-80% by 2019. The increase occurred at different times/rates for different art units. Since 2019

INTRODUCTORY COMMENTS RE: BIOTECH/PHARMA EXTENDED PATENT FAMILIES In complex art areas like biotech/biopharma, patent strategy is about building extended patent families in key jurisdictions throughout the world, and especially in the U.S. This buildout should include numerous issued patents of different claim types and scope, from numerous related patent filings. These related filings typically share a lot of common disclosure, with numerous subsequent filings, typically pro

The $AMRN/Vascepa story... A sad 🥲 but insightful🤔 story about the value of U.S. biopharma patents From ~$23/share to ~$1/share in ~5 yrs Vascepa - the "good" fatty acid in fish oil • Approved for 2 indications ⇨ Pts with very high blood trigs ⇨ Cardiovascular risk reduction • Existing U.S. patents cover Indication 2 and mfg method 📅 Fall 2018 • Vascepa Reduce-It Ph3 cardiovascular risk results • Landmark cardiovascular risk Study ⇨ https://lnkd.in/g4AJ4fhK $$$$AMRN ~$23/s

If you are interested in learning more about prior patent term extension filings, the USPTO and FDA provide some helpful links, which are provided in this post. Two ways that the term of a patent can be extended* are PTA and PTE: 1) Patent Term Adjustment (PTA) is based on delays during patent examination by the USPTO, and 2) Patent Term Extension (PTE) is based on the time it takes a drug from getting the OK from the FDA to start clinical trials to the date of approval as l

March 26, 2023 The U.S. Supreme Court will hear oral arguments tomorrow in Amgen v. Sanofi, an important biotech enablement case. The...